Lakewood-Amedex joins B2i Digital’s featured company lineup

B2i Digital added Lakewood-Amedex Biotherapeutics as a Featured Company on Aug. 25, 2026, giving the clinical-stage biotech broader visibility as it prepares a Phase 2a study of Nu-3 in infected diabetic foot ulcers. The move spotlights a lead program aimed at antibiotic-resistant infections and a company with a sizable patent estate and a planned clinical path into Phase 2b.

Why it matters: - Lakewood-Amedex is trying to advance Nu-3, a topical Bisphosphocin® gel, in infected diabetic foot ulcers, a market tied to diabetes, wound care and antibiotic resistance. - B2i Digital’s Featured Company program can expand the company’s reach to retail and institutional investors ahead of a key clinical readout. - The program could matter for investors watching for new approaches to infections that no longer respond well to standard antibiotics.

What happened: - B2i Digital named Lakewood-Amedex Biotherapeutics its newest Featured Company on Aug. 25, 2026. - The Sarasota, Florida-based clinical-stage biotechnology company is preparing a Phase 2a proof-of-concept trial of Nu-3 in infected diabetic foot ulcers. - Lakewood-Amedex said the trial is being built to support a larger Phase 2b study.

The details: - Lakewood-Amedex develops the Bisphosphocin® class, described as fast-acting, broad-spectrum antimicrobials aimed at infectious diseases and antibiotic-resistant bacterial strains. - Nu-3 is a topically delivered gel designed for infected diabetic foot ulcers. - The planned Phase 2a study will evaluate Nu-3 at three concentrations: 2%, 5% and 10%. - David G. Armstrong, DPM, M.D., Ph.D., Distinguished Professor of Surgery and Neurological Surgery at the Keck School of Medicine of USC, accepted the role of Study Chair in June and will also serve as a Scientific Advisor on the diabetic foot ulcer program. - A preclinical package reported in July found Nu-3 was well tolerated in an FDA-required safety study at doses substantially higher than those planned for Phase 2a. - The company said Nu-3 showed very low systemic exposure and no inhibition of wound healing in that preclinical work. - Lakewood-Amedex says Bisphosphocin® compounds act by destabilizing the bacterial cell membrane in a pH- and concentration-dependent way, typically within one minute of exposure. - The company reports Nu-3 did not induce resistance in a serial passage experiment. - Nu-3 has shown broad-spectrum in vitro activity against bacteria carrying a diverse range of resistance mechanisms. - Lakewood-Amedex says the diabetic foot ulcer opportunity is large because the World Health Organization counts 830 million people living with diabetes, about a third of whom will develop a diabetic foot ulcer. - The company says roughly half of diabetic foot ulcers become infected. - The company also says 15% to 20% of infected cases involve resistant pathogens, primarily MRSA. - Lakewood-Amedex reports an intellectual property estate of 72 issued patents and 29 pending applications covering the Bisphosphocin® class, Nu-3 formulations, use patents and process patents. - The company says principal filings run through 2038 and recent applications through 2044. - Lakewood-Amedex began trading on the Nasdaq Capital Market under the symbol LABT after a direct listing in April 2026. - B2i Digital said a full company profile is coming soon to featured companies.

Between the lines: - The Featured Company designation gives Lakewood-Amedex a marketing and investor-relations platform at a time when the company is still early in clinical development. - The emphasis on resistance data and rapid membrane disruption suggests Lakewood-Amedex is trying to differentiate Nu-3 from antibiotics that bacteria can more easily evade. - The planned study design and expert study chair point to an effort to build credibility before larger trials.

What's next: - Lakewood-Amedex is finalizing preparation of the Phase 2a study. - The company will test whether the topical gel can show safety and efficacy at the planned doses in patients with infected diabetic foot ulcers. - Positive results would support movement into Phase 2b. - B2i Digital will publish a fuller company profile on its Featured Companies page.